Usa India Malaysia covid-19 2020 Usa India Malaysia

As Biocon doubles up on capex, investors may see lower cash flow

Reading now: 483
www.livemint.com

The recent clearances to two of Biocon Biologics’ biosimilars plants, in India and in Malaysia, have cleared some of the overhang on its parent Biocon Ltd’s stock.

Delays in securing product approval in the US due to covid-19 and high capital expenditures, however, could keep a lid on the stock’s performance, which surged to an all-time high in end-April.

Biocon’s insulin glargine launch in the US could be delayed due to the surge in covid-19 cases. It has been expecting an approval in the second half of 2020.

In fact, the US Food and Drug Administration’s clearance of the Malaysian unit is a positive. Investors hope that this product will shore up revenue despite the delay.

Read more on livemint.com
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA